$JAGX

Jaguar Health (JAGX) shares rose after its subsidiary, Napo Pharmaceuticals, announced a sponsorship for an intestinal failure discussion at an Abu Dhabi conference. Napo is developing crofelemer for rare intestinal failure diseases, with a New Drug Application filing targeted for mid-2027. Earlier data showed reductions in parenteral support requirements for patients. JAGX is up 29.81% at $6.14.

Jaguar Health (JAGX) targets mid-2027 NDA filing for crofelemer in treating microvillus inclusion disease. Napo Pharmaceuticals, its subsidiary, is advancing the drug's development for intestinal failure. Recent data showed reductions in parenteral support needs in pediatric patients. The company will sponsor a panel at a pediatric gastroenterology conference in Abu Dhabi on October 30.

Jaguar Health Inc. (JAGX) stock rose 33.62% on news of drug-development progress. The company's rare-disease pipeline, including crofelemer for MVID and SBS-IF, is advancing with a pivotal trial and potential NDA filing in mid-2027. JAGX has high volatility, negative cash flow, and relies on financing. Revenue is $11.5M annually with an 82% gross margin. The company is exploring strategic alternatives and declared a special stock dividend.

Jaguar Health (NASDAQ:JAGX) shares surged 34.67% to $6.37 in after-hours trading. The company declared a special dividend of Series R Convertible Preferred Stock, convertible into common shares. It also extended debt payments to 2027. JAGX has a market cap of $9.20 million and an RSI of 45.39, trading near its yearly low.

Jaguar Health amended agreements with Uptown and Streeterville Capital to defer royalty payments to 2027, with a $750,000 monthly minimum. It extended a $6.22M note's maturity to 2027. The company also gained consent from Series P investors to issue a preferred dividend, adding a repurchase covenant. These moves aim to improve liquidity.

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Jaguar Health Announces a Special Stock Dividend Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / October 2, 2026 / Jaguar Health, Inc . ( NASDAQ: JAGX ) (“Jaguar” or

Jaguar Health, Inc. (JAGX) announced a special stock dividend of Series R Convertible Preferred Stock to shareholders and warrant holders as of October 13, 2026. The dividend aims to protect against dilution while the company explores strategic alternatives. The preferred stock will convert into common stock on November 2, 2026. Jaguar is focused on developing oral crofelemer for rare intestinal failure diseases, with an expected NDA filing in mid-2027.

Jaguar Health (JAGX) announced that preliminary results of an open-label study of its crofelemer powder for oral solution in adult short bowel syndrome with intestinal failure (SBS-IF) patients will be presented at the American College of Gastroenterology Annual Scientific Meeting. The company is also conducting a Phase 2 clinical trial in adult Type 1 SBS patients, with results expected in early 2027.

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on January 19, 2021, Jaguar Health, Inc. (the “Company”) issued and sold to Streeterville Capital, LLC (“Streeterville”) a secured promissory note in the original principal amount of $6,220,812.50 (as

ADARx (ADRX) priced its IPO at $17/share, raising $446.3M, with AbbVie investing $100M. CNSY (CNSY) secured reimbursement with Blue Cross Blue Shield. JAGX (JAGX) completed a reverse stock split. AGL (AGL) expanded its partnership with Springfield Clinic. ONCO (ONCO) agreed to acquire Realbotix. All stocks traded higher.